The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PETS | -29.27% | -88.89% | -35.56% | +364% |
| S&P | +14.5% | +93.32% | +14.09% | +608% |
PetMed Express, Inc. engages in the provision of markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The firm markets its products through national television, online and direct mail or print advertising campaigns. The company was founded in January 1996 and is headquartered in Delray Beach, FL.
Its quarterly results included a surprise net loss.
The online pet pharmacy is in the early stages of expanding its sights, making it an interesting buy for risk-tolerant investors.
| Q1 2025 | YOY Change | |
|---|---|---|
| Revenue | $46.47M | -30.1% |
| Gross Profit | $16.87M | 3.6% |
| Gross Margin | 36.31% | 11.8% |
| Market Cap | $86.55M | -14.6% |
| Market Cap / Employee | $0.50M | 0.0% |
| Employees | 173 | -39.7% |
| Net Income | -$11.64M | -132.1% |
| EBITDA | -$1.25M | 38.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q1 2025 | YOY Change | |
|---|---|---|
| Net Cash | $54.72M | -1.0% |
| Accounts Receivable | $2.32M | -29.4% |
| Inventory | 16.2 | -43.3% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.54M | -46.2% |
| Short Term Debt | $0.46M | 0.4% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -3.87% | 0.3% |
| Return On Invested Capital | 10.68% | -7.1% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $4.62M | -21.3% |
| Operating Free Cash Flow | $7.01M | -1.6% |
| Metric | Q4 2024 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 450.47 | - | |||
| Price to Book | 0.89 | 0.79 | 1.03 | 0.90 | -11.17% |
| Price to Sales | 0.31 | 0.30 | 0.40 | 0.38 | 9.45% |
| Price to Tangible Book Value | 1.46 | 1.28 | 1.67 | 1.45 | -11.86% |
| Price to Free Cash Flow TTM | 150.24 | - | |||
| Enterprise Value to EBITDA | 6.57 | 11.86 | 43.47 | -26.25 | 21.45% |
| Free Cash Flow Yield | 0.7% | - | |||
| Return on Equity | -2.4% | -1.0% | 0.4% | -6.9% | 5.39% |
| Total Debt | $1.32M | $1.21M | $1.11M | $1.00M | -31.50% |
PETS earnings call for the period ending September 30, 2021.
PETS earnings call for the period ending June 30, 2021.
PETS earnings call for the period ending March 31, 2021.
PETS earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
